---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-027210"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2025-09-12T23:59:59+00:00"
generated_at: "2026-05-17T06:45:11.806291+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics files prospectus supplement for up to $5.83M ATM offering

## Summary
- Company may sell up to $5,830,572 of common stock through H.C. Wainwright as sales agent.
- No shares had been sold under prior ATM agreement as of September 12, 2025.
- Shelf registration statement S-3 (333-284834) declared effective by SEC on September 10, 2025.
- Common stock par value $0.0001 per share; proceeds for general corporate purposes.

## SEC filing metadata
- accession: 0001641172-25-027210
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2025-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000164117225027210/0001641172-25-027210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000164117225027210/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-027210
- JSON: https://secwatch.observer/filing/0001641172-25-027210.json
- Plain text: https://secwatch.observer/filing/0001641172-25-027210.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.